Literature DB >> 27842331

Chemoprevention in African American Men With Prostate Cancer.

Nagi B Kumar1, Julio M Pow-Sang, Philippe E Spiess, Jong Y Park, Ganna Chornokur, Andrew R Leone, Catherine M Phelan.   

Abstract

BACKGROUND: Recommendations for cancer screening are uncertain for the early detection or prevention of prostate cancer in African American men. Thus, chemoprevention strategies are needed to specifically target African American men.
METHODS: The evidence was examined on the biological etiology of disparities in African Americans related to prostate cancer. Possible chemopreventive agents and biomarkers critical to prostate cancer in African American men were also studied.
RESULTS: High-grade prostatic intraepithelial neoplasia may be more prevalent in African American men, even after controlling for age, prostate-specific antigen (PSA) level, abnormal results on digital rectal examination, and prostate volume. Prostate cancer in African American men can lead to the overexpression of signaling receptors that may mediate increased proliferation, angiogenesis, and decreased apoptosis. Use of chemopreventive agents may be useful for select populations of men.
CONCLUSIONS: Green tea catechins are able to target multiple pathways to address the underlying biology of prostate carcinogenesis in African American men, so they may be ideal as a chemoprevention agent in these men diagnosed with high-grade prostatic intraepithelial neoplasia.

Entities:  

Mesh:

Year:  2016        PMID: 27842331     DOI: 10.1177/107327481602300413

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  1 in total

Review 1.  Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison.

Authors:  Kang Cui; Xiangnan Li; Yabing Du; Xiance Tang; Seiji Arai; Yiwei Geng; Ying Xi; Han Xu; Yue Zhou; Wang Ma; Tengfei Zhang
Journal:  Oncotarget       Date:  2017-05-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.